Appetite stimulants for patients with cancer: current evidence for clinical practice.

The incidence of neoplastic diseases has increased worldwide, with an estimated global burden of 19.3 million incident cases and 10 million deaths in 2020-a considerable increase compared with 9.6 million deaths in 2018. One of the most prevalent problems faced by patients with cancer and their physicians is malnutrition. It is estimated that patients with cancer have important nutritional alterations in 25% to 70% of cases, which directly affects many spheres of patient care and well-being, including quality of life, treatment toxicity, and survival outcomes. Despite the overwhelming need to address this pressing issue, current evidence in terms of pharmacologic interventions for cancer-related anorexia remains inconclusive, and there is no current standard of care for patients with cancer-related anorexia. Nonetheless, international guidelines recommend promoting anabolism through nutritional, physical, and pharmacologic therapies. In this review, the available information is summarized regarding pharmacologic therapies to treat cancer-related anorexia and findings are highlighted from a clinical stance.

[1]  O. Arrieta,et al.  Baseline Dysgeusia in Chemotherapy-Naïve Non-Small Cell Lung Cancer Patients: Association with Nutrition and Quality of Life , 2020, Nutrition and cancer.

[2]  W. Simonson.  Should mirtazapine be used to improve appetite and reverse weight loss? , 2019, Geriatric nursing.

[3]  J. Furuse,et al.  A multicenter, open‐label, single‐arm study of anamorelin (ONO‐7643) in advanced gastrointestinal cancer patients with cancer cachexia , 2019, Cancer.

[4]  S. Elad,et al.  Systematic review of agents for the management of cancer treatment-related gastrointestinal mucositis and clinical practice guidelines. , 2019, Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer.

[5]  M. Norris,et al.  Use of cyproheptadine to stimulate appetite and body weight gain: A systematic review , 2019, Appetite.

[6]  A. Khan,et al.  Efficacy of zinc sulfate on concurrent chemoradiotherapy induced taste alterations in oral cancer patients: A double blind randomized controlled trial , 2019, Pakistan journal of medical sciences.

[7]  H. Okamoto,et al.  Low-dose of olanzapine has ameliorating effects on cancer-related anorexia , 2019, Cancer management and research.

[8]  A. Vigano,et al.  Health-related quality of life across cancer cachexia stages. , 2019, Annals of palliative medicine.

[9]  Mellar P. Davis,et al.  Sarcopenia associated with chemotherapy and targeted agents for cancer therapy. , 2019, Annals of palliative medicine.

[10]  J. Ferlay,et al.  Global cancer incidence in older adults, 2012 and 2035: A population‐based study , 2018, International journal of cancer.

[11]  Meredith L. Howard,et al.  Efficacy and Safety of Appetite-Stimulating Medications in the Inpatient Setting , 2018, The Annals of pharmacotherapy.

[12]  M. Badowski,et al.  Dronabinol oral solution in the management of anorexia and weight loss in AIDS and cancer , 2018, Therapeutics and clinical risk management.

[13]  L. Oñate-Ocaña,et al.  The effect of nabilone on appetite, nutritional status, and quality of life in lung cancer patients: a randomized, double-blind clinical trial , 2018, Supportive Care in Cancer.

[14]  M. Korc,et al.  Cancer-associated cachexia , 2018, Nature Reviews Disease Primers.

[15]  T. Tsuji,et al.  Anamorelin (ONO‐7643) for the treatment of patients with non–small cell lung cancer and cachexia: Results from a randomized, double‐blind, placebo‐controlled, multicenter study of Japanese patients (ONO‐7643‐04) , 2017, Cancer.

[16]  Masaharu Nakayama,et al.  Synthesis and biological evaluation of novel selective androgen receptor modulators (SARMs) Part III: Discovery of 4-(5-oxopyrrolidine-1-yl)benzonitrile derivative 2f as a clinical candidate. , 2017, Bioorganic & medicinal chemistry.

[17]  S. Gambhir,et al.  Effect of Mirtazapine on Gastric Emptying in Patients with Cancer-associated Anorexia , 2017, Indian journal of palliative care.

[18]  T. Keck,et al.  Dietary supplementation with n-3-fatty acids in patients with pancreatic cancer and cachexia: marine phospholipids versus fish oil - a randomized controlled double-blind trial , 2017, Lipids in Health and Disease.

[19]  C. Thompson,et al.  Cancer cell metabolism: the essential role of the nonessential amino acid, glutamine , 2017, The EMBO journal.

[20]  A. Abernethy,et al.  ROMANA 3: a phase 3 safety extension study of anamorelin in advanced non-small-cell lung cancer (NSCLC) patients with cachexia , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[21]  T. Hitaka,et al.  Synthesis and biological evaluation of novel selective androgen receptor modulators (SARMs). Part II: Optimization of 4-(pyrrolidin-1-yl)benzonitrile derivatives. , 2017, Bioorganic & medicinal chemistry letters.

[22]  Alan D. Lopez,et al.  Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015: A Systematic Analysis for the Global Burden of Disease Study , 2017, JAMA oncology.

[23]  Vickie Baracos,et al.  ESPEN guidelines on nutrition in cancer patients. , 2017, Clinical nutrition.

[24]  E. Karabulut,et al.  The effect of glutamine and arginine-enriched nutritional support on quality of life in head and neck cancer patients treated with IMRT. , 2016, Clinical nutrition ESPEN.

[25]  A. Abernethy,et al.  Anamorelin in patients with non-small-cell lung cancer and cachexia (ROMANA 1 and ROMANA 2): results from two randomised, double-blind, phase 3 trials. , 2016, The Lancet Oncology.

[26]  A. Fortin,et al.  Improving Quality of Life With Nabilone During Radiotherapy Treatments for Head and Neck Cancers , 2016, The Annals of otology, rhinology, and laryngology.

[27]  K. Eguchi,et al.  Anamorelin (ONO-7643) in Japanese patients with non-small cell lung cancer and cachexia: results of a randomized phase 2 trial , 2016, Supportive Care in Cancer.

[28]  V. Baracos,et al.  Nutritional Status, Body Surface, and Low Lean Body Mass/Body Mass Index Are Related to Dose Reduction and Severe Gastrointestinal Toxicity Induced by Afatinib in Patients With Non-Small Cell Lung Cancer. , 2015, The oncologist.

[29]  P. Ravasco,et al.  Eicosapentaenoic acid in cancer improves body composition and modulates metabolism. , 2015, Nutrition.

[30]  A. Mohar,et al.  Effects of an oral nutritional supplement containing eicosapentaenoic acid on nutritional and clinical outcomes in patients with advanced non-small cell lung cancer: randomised trial. , 2014, Clinical nutrition.

[31]  G. Biolo,et al.  Muscle contractile and metabolic dysfunction is a common feature of sarcopenia of aging and chronic diseases: from sarcopenic obesity to cachexia. , 2014, Clinical nutrition.

[32]  N. Mccorry,et al.  Use of corticosteroids for anorexia in palliative medicine: a systematic review. , 2014, Journal of palliative medicine.

[33]  Olga Hilas,et al.  Potential role of mirtazapine in underweight older adults. , 2014, The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists.

[34]  C. Delporte.  Structure and Physiological Actions of Ghrelin , 2013, Scientifica.

[35]  E. Bruera,et al.  Effects of melatonin on appetite and other symptoms in patients with advanced cancer and cachexia: a double-blind placebo-controlled trial. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  P. Malfertheiner,et al.  L-Carnitine-supplementation in advanced pancreatic cancer (CARPAN) - a randomized multicentre trial , 2012, Nutrition Journal.

[37]  Thomas J. Smith,et al.  A Randomized, Placebo Controlled Trial of Oral Zinc for Chemotherapy-Related Taste and Smell Disorders , 2012, Journal of pain & palliative care pharmacotherapy.

[38]  L. Oñate-Ocaña,et al.  Association of Nutrition Parameters Including Bioelectrical Impedance and Systemic Inflammatory Response With Quality of Life and Prognosis in Patients With Advanced Non-Small-Cell Lung Cancer: A Prospective Study , 2012, Nutrition and cancer.

[39]  L. Murray,et al.  Thalidomide for managing cancer cachexia. , 2012, The Cochrane database of systematic reviews.

[40]  G. Mantovani,et al.  Randomized phase III clinical trial of a combined treatment with carnitine + celecoxib ± megestrol acetate for patients with cancer-related anorexia/cachexia syndrome. , 2012, Clinical nutrition.

[41]  T. S. Frode,et al.  Fish Oil Supplement Alters Markers of Inflammatory and Nutritional Status in Colorectal Cancer Patients , 2012, Nutrition and cancer.

[42]  Jens Knud Larsen.  Mirtazapine versus other antidepressive agents for depression , 2012, Ugeskrift for laeger.

[43]  M. Schena,et al.  Effect of n-3 fatty acids on patients with advanced lung cancer: a double-blind, placebo-controlled study , 2011, British Journal of Nutrition.

[44]  E. Bruera,et al.  Preliminary report: vitamin D deficiency in advanced cancer patients with symptoms of fatigue or anorexia. , 2011, The oncologist.

[45]  N. Macdonald,et al.  Delta-9-tetrahydrocannabinol may palliate altered chemosensory perception in cancer patients: results of a randomized, double-blind, placebo-controlled pilot trial. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[46]  A. Asakawa,et al.  Zinc as an appetite stimulator - the possible role of zinc in the progression of diseases such as cachexia and sarcopenia. , 2011, Recent patents on food, nutrition & agriculture.

[47]  T. Reiman,et al.  Supplementation with fish oil increases first‐line chemotherapy efficacy in patients with advanced nonsmall cell lung cancer , 2011, Cancer.

[48]  G. Rosti,et al.  Nutritional intervention for improving treatment tolerance in cancer patients , 2011, Current opinion in oncology.

[49]  E. Smit,et al.  Oral nutritional supplements containing (n-3) polyunsaturated fatty acids affect the nutritional status of patients with stage III non-small cell lung cancer during multimodality treatment. , 2010, The Journal of nutrition.

[50]  I. Bosaeus,et al.  Effects by daily long term provision of ghrelin to unselected weight‐losing cancer patients , 2010, Cancer.

[51]  G. Biolo,et al.  Consensus definition of sarcopenia, cachexia and pre-cachexia: joint document elaborated by Special Interest Groups (SIG) "cachexia-anorexia in chronic wasting diseases" and "nutrition in geriatrics". , 2010, Clinical nutrition.

[52]  A. Laviano,et al.  Influence of taste disorders on dietary behaviors in cancer patients under chemotherapy , 2010, Nutrition journal.

[53]  I. Tannock,et al.  Phase II Trial of Mirtazapine for Cancer-Related Cachexia and Anorexia , 2010, The American journal of hospice & palliative care.

[54]  O. Arrieta,et al.  Association of nutritional status and serum albumin levels with development of toxicity in patients with advanced non-small cell lung cancer treated with paclitaxel-cisplatin chemotherapy: a prospective study , 2010, BMC Cancer.

[55]  M. Fallon,et al.  Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain. , 2010, Journal of pain and symptom management.

[56]  P. Contu,et al.  Randomized phase III clinical trial of five different arms of treatment in 332 patients with cancer cachexia. , 2010, The oncologist.

[57]  A. Asakawa,et al.  Orally administered zinc increases food intake via vagal stimulation in rats. , 2009, The Journal of nutrition.

[58]  A. Malfitano,et al.  Use of cannabinoid receptor agonists in cancer therapy as palliative and curative agents. , 2009, Best practice & research. Clinical endocrinology & metabolism.

[59]  T. Kirkham.  Cannabinoids and appetite: Food craving and food pleasure , 2009, International review of psychiatry.

[60]  R. Jaeschke,et al.  Effects of megestrol acetate in patients with cancer anorexia-cachexia syndrome--a systematic review and meta-analysis. , 2008, Polskie Archiwum Medycyny Wewnetrznej.

[61]  T. Šarčev,et al.  [Influence of dexamethasone on appetite and body weight in lung cancer patients]. , 2008, Medicinski pregled.

[62]  M. Ennis,et al.  Adjunctive nabilone in cancer pain and symptom management: a prospective observational study using propensity scoring. , 2008, The journal of supportive oncology.

[63]  M. Tschöp,et al.  Safety, tolerability and pharmacokinetics of intravenous ghrelin for cancer-related anorexia/cachexia: a randomised, placebo-controlled, double-blind, double-crossover study , 2008, British Journal of Cancer.

[64]  R. Pertwee,et al.  The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: Δ9‐tetrahydrocannabinol, cannabidiol and Δ9‐tetrahydrocannabivarin , 2008 .

[65]  Mellar P. Davis.  Oral nabilone capsules in the treatment of chemotherapy-induced nausea and vomiting and pain , 2008, Expert opinion on investigational drugs.

[66]  D. Osei-Hyiaman.  Endocannabinoid system in cancer cachexia , 2007, Current opinion in clinical nutrition and metabolic care.

[67]  P. García-Peris,et al.  N-3 fatty acids, cancer and cachexia: a systematic review of the literature. , 2007, The British journal of nutrition.

[68]  I. Bosaeus,et al.  Insulin Treatment in Cancer Cachexia: Effects on Survival, Metabolism, and Physical Functioning , 2007, Clinical Cancer Research.

[69]  R. Portenoy,et al.  Safety, tolerability and symptom outcomes associated with L-carnitine supplementation in patients with cancer, fatigue, and carnitine deficiency: a phase I/II study. , 2006, Journal of pain and symptom management.

[70]  G. Murray,et al.  Double-blind, placebo-controlled, randomized study of eicosapentaenoic acid diester in patients with cancer cachexia. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[71]  F. Strasser,et al.  Comparison of orally administered cannabis extract and delta-9-tetrahydrocannabinol in treating patients with cancer-related anorexia-cachexia syndrome: a multicenter, phase III, randomized, double-blind, placebo-controlled clinical trial from the Cannabis-In-Cachexia-Study-Group. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[72]  E. Leinonen,et al.  A review of the pharmacological and clinical profile of mirtazapine. , 2006, CNS drug reviews.

[73]  H. Hinterhuber,et al.  Effect of mirtazapine treatment on body composition and metabolism. , 2006, The Journal of clinical psychiatry.

[74]  G. Mantovani,et al.  Efficacy of l-carnitine administration on fatigue, nutritional status, oxidative stress, and related quality of life in 12 advanced cancer patients undergoing anticancer therapy. , 2006, Nutrition.

[75]  Mellar P. Davis,et al.  The efficacy and tolerability of long-term use of dronabinol in cancer-related anorexia: a case series. , 2005, Journal of pain and symptom management.

[76]  Mellar P. Davis,et al.  Systematic review of the treatment of cancer-associated anorexia and weight loss. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[77]  P. Novotny,et al.  An eicosapentaenoic acid supplement versus megestrol acetate versus both for patients with cancer-associated wasting: a North Central Cancer Treatment Group and National Cancer Institute of Canada collaborative effort. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[78]  K. Fearon,et al.  Reduced total energy expenditure and physical activity in cachectic patients with pancreatic cancer can be modulated by an energy and protein dense oral supplement enriched with n-3 fatty acids , 2004, British Journal of Cancer.

[79]  N. Aaronson,et al.  Effect of a protein and energy dense n-3 fatty acid enriched oral supplement on loss of weight and lean tissue in cancer cachexia: a randomised double blind trial , 2003, Gut.

[80]  D. Walsh,et al.  Established and potential therapeutic applications of cannabinoids in oncology , 2003, Supportive Care in Cancer.

[81]  S. Passik,et al.  An open-label, crossover trial of mirtazapine (15 and 30 mg) in cancer patients with pain and other distressing symptoms. , 2002, Journal of pain and symptom management.

[82]  P. Novotny,et al.  Dronabinol versus megestrol acetate versus combination therapy for cancer-associated anorexia: a North Central Cancer Treatment Group study. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[83]  J. Ross,et al.  Effect of a Fish Oil-Enriched Nutritional Supplement on Metabolic Mediators in Patients With Pancreatic Cancer Cachexia , 2001, Nutrition and cancer.

[84]  M. Tisdale,et al.  Cancer anorexia and cachexia. , 2001, Nutrition.

[85]  R. Palmiter,et al.  Leptin-regulated endocannabinoids are involved in maintaining food intake , 2001, Nature.

[86]  D. Walsh,et al.  The symptoms of advanced cancer: relationship to age, gender, and performance status in 1,000 patients , 2000, Supportive Care in Cancer.

[87]  J. Ross,et al.  Effect of Oral Eicosapentaenoic Acid on Weight Loss in Patients With Pancreatic Cancer , 2000, Nutrition and cancer.

[88]  K. Fearon,et al.  The effect of an oral nutritional supplement enriched with fish oil on weight-loss in patients with pancreatic cancer , 1999, British Journal of Cancer.

[89]  F. Kokot,et al.  Effects of Neuropeptide Y on Appetite , 1999, Mineral and Electrolyte Metabolism.

[90]  G. Kelly.  L-Carnitine: therapeutic applications of a conditionally-essential amino acid. , 1998, Alternative medicine review : a journal of clinical therapeutic.

[91]  E. Bruera,et al.  A Review of the Drug Treatment of Cachexia Associated with Cancer , 1998, Drugs.

[92]  J. Cockcroft,et al.  Vitamin E and cardiovascular protection in diabetes , 1997, BMJ.

[93]  J. O'fallon,et al.  Pentoxifylline for treatment of cancer anorexia and cachexia? A randomized, double-blind, placebo-controlled trial. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[94]  K. Shepard,et al.  Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS. , 1995, Journal of pain and symptom management.

[95]  D. Walsh,et al.  A Phase II Study of Delta-9-Tetrahydrocannabinol for Appetite Stimulation in Cancer-Associated Anorexia , 1994, Journal of palliative care.

[96]  R. Chlebowski,et al.  Hydrazine sulfate in cancer patients with weight loss. A placebo‐controlled clinical experience , 1987, Cancer.

[97]  P. Déchelotte,et al.  Glutamine and the regulation of intestinal permeability: from bench to bedside , 2017, Current opinion in clinical nutrition and metabolic care.

[98]  S. Elad,et al.  Systematic review of agents for the management of gastrointestinal mucositis in cancer patients , 2012, Supportive Care in Cancer.

[99]  D. Cardona.  [Pharmacological therapy of cancer anorexia-cachexia]. , 2006, Nutricion hospitalaria.

[100]  E. Bruera,et al.  Effect of fish oil on appetite and other symptoms in patients with advanced cancer and anorexia/cachexia: a double-blind, placebo-controlled study. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[101]  K. Fearon,et al.  The effect of polyunsaturated fatty acids on the progress of cachexia in patients with pancreatic cancer. , 1996, Nutrition.